INTRA-CAVITY RONKOLEUKIN IMMUNOTHERAPY IN TREATMENT RESISTANT PATIENTS WITH MALIGNANT EFFUSIONS

Download full text PDF
Issue: 
11
Year: 
2015

K. Titov (1), Candidate of Medical Sciences; Professor M. Kiselevsky (2), MD; I. Shubina (2), Doctor of Biological Sciences; Professor R. Izrailov (1), MD; N. Semenov (1) 1 -Moscow Clinical Research Centre 2 -N.N. Вlokhin Russian Сancer Research Centre, Moscow

The study evaluated feasibility, safety and effectiveness in combination with recombinant interleukin-2 (IL2) used for antitumor immunotherapy. The clinical study involved cancer patients with metastatic effusions resistant to systemic chemotherapy. The results showed that intra-cavity IL2-immunotherapy was highly effective and well tolerated in treatment of patients with malignant effusions.
Keywords: 
immunotherapy
metastatic effusions
interleukin-2

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Sel'chuk V.Ju., Bychkov M.B., Kiselevskij M.B. Opuholevye serozity / M.: Prakticheskaja meditsina, 2011; s. 278.
  2. Titov K.S., Demidov L.V, Shubina I.Zh. i dr. Sravnenie effektivnosti i perenosimosti vnutribrjushinnoj kletochnoj i IL-2-immunoterapii u bol'nyh s himiorezistentnymi astsitnymi formami raka zheludka // Ros. onkol. zhurn. – 2014; 3: 24–8.
  3. Kiselevskij M.V. Adoptivnaja immunoterapija pri zlokachestvennyh opuholjah // Vestnik RAMN. – 2003; 1: 40–4.
  4. Xue S., Stauss H. Enhancing immune responses for cancer therapy // Cell Mol. Immunol. – 2007; 4 (3): 173–84.
  5. Manjili M. Revisiting cancer immunoediting by understanding cancer immune complexity // J. Pathol. – 2011; 224 (1): 5–9.
  6. Wang E., Panelli M., Monsurró V. et al. A global approach to tumor immunology // Cell Mol. Immunol. – 2004; 1 (4): 256–65.
  7. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects // J. Intern. Med. – 2009; 1: 154–81.
  8. June C. Adoptive T cell therapy for cancer in the clinic // J. Clin. Invest. – 2007; 117 (6): 1466–76.
  9. Rosenberg S., Lotze M., Yang J. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer // J. Natl. Cancer Inst. – 1993; 85 (8): 622–32.
  10. Hontscha C., Borck Y., Zhou H. et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) // J. Cancer Res. Clin. Oncol. – 2011; 137 (2): 305–10.
  11. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors // J. Cancer. – 2011; 2: 363–8.
  12. Liu X., Li D., Zhang C. et al. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2 // Chin. Med. Sci. J. – 1993; 8(3): 186–9.
  13. Ruggeri L., Capanni M., Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants // Science. – 2002; 295: 2097–100.